197 related articles for article (PubMed ID: 32311473)
1. Risk of target non-attainment in obese compared to non-obese patients in calculated linezolid therapy.
Ehmann L; Simon P; Busse D; Petroff D; Dorn C; Huisinga W; Dietrich A; Zeitlinger M; Wrigge H; Kloft C
Clin Microbiol Infect; 2020 Sep; 26(9):1222-1228. PubMed ID: 32311473
[TBL] [Abstract][Full Text] [Related]
2. Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.
Minichmayr IK; Schaeftlein A; Kuti JL; Zeitlinger M; Kloft C
Clin Pharmacokinet; 2017 Jun; 56(6):617-633. PubMed ID: 27753002
[TBL] [Abstract][Full Text] [Related]
3. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.
Busse D; Simon P; Schmitt L; Petroff D; Dorn C; Dietrich A; Zeitlinger M; Huisinga W; Michelet R; Wrigge H; Kloft C
Clin Pharmacokinet; 2022 May; 61(5):655-672. PubMed ID: 34894344
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients.
Cojutti P; Pai MP; Pea F
Clin Pharmacokinet; 2018 Aug; 57(8):989-1000. PubMed ID: 29080937
[TBL] [Abstract][Full Text] [Related]
5. High-Dosage Fosfomycin Results in Adequate Plasma and Target-Site Exposure in Morbidly Obese and Nonobese Nonhyperfiltration Patients.
Busse D; Simon P; Petroff D; El-Najjar N; Schmitt L; Bindellini D; Dietrich A; Zeitlinger M; Huisinga W; Michelet R; Wrigge H; Kloft C
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0230221. PubMed ID: 35603536
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic evaluation of linezolid administered intravenously in obese patients with pneumonia.
Xie F; Mantzarlis K; Malliotakis P; Koulouras V; Degroote S; Koulenti D; Blot S; Boussery K; Van Bocxlaer J; Colin P;
J Antimicrob Chemother; 2019 Mar; 74(3):667-674. PubMed ID: 30535122
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of linezolid in plasma/cerebrospinal fluid in patients with cerebral hemorrhage after lateral ventricular drainage by Monte Carlo simulation.
Wu X; Tang Y; Zhang X; Wu C; Kong L
Drug Des Devel Ther; 2018; 12():1679-1684. PubMed ID: 29928111
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics and Target Attainment of Meropenem in Plasma and Tissue of Morbidly Obese Patients after Laparoscopic Intraperitoneal Surgery.
Wittau M; Scheele J; Kurlbaum M; Brockschmidt C; Wolf AM; Hemper E; Henne-Bruns D; Bulitta JB
Antimicrob Agents Chemother; 2015 Oct; 59(10):6241-7. PubMed ID: 26248353
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Linezolid Pharmacokinetics in Critically Ill Obese Patients with Severe Skin and Soft Tissue Infections.
Blackman AL; Jarugula P; Nicolau DP; Chui SH; Joshi M; Heil EL; Gopalakrishnan M
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33257446
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery.
Wittau M; Paschke S; Kurlbaum M; Scheele J; Ly NS; Hemper E; Kornmann M; Henne-Bruns D; Bulitta JB
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795367
[TBL] [Abstract][Full Text] [Related]
11. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis.
Brill MJ; Houwink AP; Schmidt S; Van Dongen EP; Hazebroek EJ; van Ramshorst B; Deneer VH; Mouton JW; Knibbe CA
J Antimicrob Chemother; 2014 Mar; 69(3):715-23. PubMed ID: 24214905
[TBL] [Abstract][Full Text] [Related]
12. Prolonged infusion of linezolid is associated with improved pharmacokinetic/pharmacodynamic (PK/PD) profiles in patients with external ventricular drains.
Zhao W; Kong L; Wu C; Wu X
Eur J Clin Pharmacol; 2021 Jan; 77(1):79-86. PubMed ID: 32812063
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy.
Ide T; Takesue Y; Ikawa K; Morikawa N; Ueda T; Takahashi Y; Nakajima K; Takeda K; Nishi S
Int J Antimicrob Agents; 2018 May; 51(5):745-751. PubMed ID: 29425834
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients.
Chung EK; Fleming MR; Cheatham SC; Kays MB
Ann Pharmacother; 2017 Mar; 51(3):209-218. PubMed ID: 28168884
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.
Chung EK; Cheatham SC; Fleming MR; Healy DP; Kays MB
J Clin Pharmacol; 2017 Mar; 57(3):356-368. PubMed ID: 27530916
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Pharmacodynamics of Linezolid in Patients With Sepsis Receiving Continuous Venovenous Hemofiltration and Extended Daily Hemofiltration.
Zheng J; Sun Z; Sun L; Zhang X; Hou G; Han Q; Li X; Liu G; Gao Y; Ye M; Wang H; Yu K
J Infect Dis; 2020 Mar; 221(Suppl 2):S279-S287. PubMed ID: 32176792
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients.
Tietjen AK; Kroemer N; Cattaneo D; Baldelli S; Wicha SG
Br J Clin Pharmacol; 2022 Feb; 88(4):1835-1844. PubMed ID: 34622478
[TBL] [Abstract][Full Text] [Related]
18. Linezolid Concentrations in Plasma and Subcutaneous Tissue are Reduced in Obese Patients, Resulting in a Higher Risk of Underdosing in Critically Ill Patients: A Controlled Clinical Pharmacokinetic Study.
Simon P; Busse D; Petroff D; Dorn C; Ehmann L; Hochstädt S; Girrbach F; Dietrich A; Zeitlinger M; Kees F; Kloft C; Wrigge H
J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32283731
[No Abstract] [Full Text] [Related]
19. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
Maseda E; Grau S; Luque S; Castillo-Mafla MP; Suárez-de-la-Rica A; Montero-Feijoo A; Salgado P; Gimenez MJ; García-Bernedo CA; Gilsanz F; Roberts JA
Crit Care; 2018 Apr; 22(1):94. PubMed ID: 29655372
[TBL] [Abstract][Full Text] [Related]
20. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
Dong H; Xie J; Chen L; Wang T; Sun J; Zhao Y; Dong Y
Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
